Splenic marginal zone lymphoma in Sweden 2000–2020: Increasing rituximab use and better survival in the elderly

Splenic marginal zone lymphoma in Sweden 2000–2020: Increasing rituximab use and better survival in the elderly

Abstract The treatment of splenic marginal zone lymphoma is debated: splenectomy (the old standard‐of‐care) is better than chemotherapy but maybe not better than rituximab‐containing treatment. We examined all 358 patients diagnosed with splenic marginal zone lymphoma in Sweden 2000–2020. The median...

Full description

Bibliographic Details
Main Authors: Henna‐Riikka Junlén, Kristina Sonnevi, Ola Lindén, Mats Hellström, Mariana Villegas Scivetti, Mikael Olsson, Ida Tufvesson, Ann‐Sofie Johansson, Björn Engelbrekt Wahlin
Format: Article
Language:English
Published: Wiley 2023-08-01
Series:eJHaem
Subjects:
population‐based
rituximab
splenectomy
splenic marginal zone lymphoma
survival
Online Access:https://doi.org/10.1002/jha2.696

Internet

https://doi.org/10.1002/jha2.696

Similar Items